NCT04882540

A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of a Single and Multiple Oral Doses of Brivaracetam in Healthy Adult Chinese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to assess the pharmacokinetics, safety, and tolerability of brivaracetam after a single dose and multiple doses in healthy adult Chinese Study Participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	brivaracetam	* Pharmaceutical form: Film-coated tablets * Concentration: 100 mg tablets * Route of administration: Oral use

Timeline

• Start date: 2021-05-19
• Primary completion: 2021-06-08
• Completion: 2021-06-08
• First posted: 2021-05-12
• Last updated: 2023-03-13
• Results posted: 2023-03-13

Locations

1 site across 1 country: China